<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytarabune ocfosfate (SPAC) is rapidly transformed into <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ara-C) when orally administered </plain></SENT>
<SENT sid="1" pm="."><plain>The pharmacokinetics of SPAC was studied in six patients with <z:hpo ids='HP_0011009'>acute</z:hpo> non-lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ANLL) and/or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) after oral administration of SPAC at 100 to 400 mg/day for 14 days </plain></SENT>
<SENT sid="2" pm="."><plain>Plasma ara-C concentrations reached a plateau in 48 to 96 hours after initiation of SPAC administration, remained at this or a little higher level until one day after its termination and were less than 1 ng/ml 8 days after the termination </plain></SENT>
<SENT sid="3" pm="."><plain>From <z:hpo ids='HP_0000001'>all</z:hpo> of pharmacokinetic data, the oral administration of SPAC at 150 to 300 mg/m2/day was pharmacokinetically concluded to be comparable to the continuous infusion of ara-C at 20 mg/m2/day </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the patients could receive SPAC for 14 days </plain></SENT>
<SENT sid="5" pm="."><plain>SPAC is considered to be useful for consolidation or maintenance chemotherapy of ANLL or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> outpatients who are unable to undergo intensive chemotherapy </plain></SENT>
</text></document>